Shares of Haemonetics (HAE) have been strong performers lately, with the stock up 13.4% over the past month. The stock hit a new 52-week high of $97.35 in the previous session. Haemonetics has gained 12.5% since the start of the year compared to the 3.8% move for the Zacks Medical sector and the 2.9% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Sc ...

Haemonetics Corporation (HAE) delivered adjusted earnings per share (EPS) of 90 cents for the fourth quarter of fiscal 2024, up 16.9% year over year. The bottom line surpassed the Zacks Consensus Estimate by 2.3%.On a GAAP basis, EPS was 40 cents, down 29.8% from the prior-year quarter’s levels.For the full year, adjusted earnings were $3.96 per share, up 30.7% from the year-ago period’s figure. It beats the Zacks Consensus Estimate by 03%.Total RevenuesRevenues increased 12.8% to $343.3 million in the four ...

Haemonetics Corporation (NYSE:HAE) Q4 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Olga Guyette - Senior Director of Investor Relations and Treasury Christopher Simon - President and Chief Executive Officer James D'Arecca - Executive Vice President and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuno Group Larry Solow - CJS Securities Joanne Wuensch - Citi Andrew Cooper - Raymond James Mike Matson - Needham & Company Michael Petusky - Barrington Rese ...

For the quarter ended March 2024, Haemonetics (HAE) reported revenue of $343.29 million, up 12.8% over the same period last year. EPS came in at $0.90, compared to $0.77 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $326.95 million, representing a surprise of +5.00%. The company delivered an EPS surprise of +2.27%, with the consensus EPS estimate being $0.88.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...

Haemonetics (HAE) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.27%. A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $0.97 per share when it actually produced earnings of $1.04, delive ...

Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemonetics Reports Fourth Quarter and Fiscal 2024 Results; Provides Fiscal 2025 Guidance Boston, MA, May 9, 2024 - Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quart ...

Financial release accessible onlineBOSTON, May 9, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024, are available on its Investor Relations website.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 9, 2024. The conference call and webcast can be accessed with the following information: Teleconf ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Royal Philips (PHG) and Haemonetics (HAE) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis ...

In its upcoming report, Haemonetics (HAE) is predicted by Wall Street analysts to post quarterly earnings of $0.88 per share, reflecting an increase of 14.3% compared to the same period last year. Revenues are forecasted to be $326.95 million, representing a year-over-year increase of 7.4%.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ove ...